sFlt-1/PlGF Ratio as a Predictive Marker in Women with Suspected Preeclampsia: An Economic Evaluation from a Swiss Perspective

Table 4

Comparison of costs for the no-test and test (sFlt-1/PlGF) strategies and difference in total and per patient costs.

Service	No-test strategy		Test strategy		Difference (€)
		Cost (€)		Cost (€)
Initial consultation	6084	3,228,220	6084	3,228,220	—
Outpatient care
Low	1655	13,068,335	2185	17,248,215	+4,179,880
Intermediate	1655	17,452,138	2498	26,666,335	+9,214,197
Intermediate (after hospitalization)	1613	22,116,244	580	8,611,745	–13,504,499
Hospitalization
Suspected preeclampsia with birth	583	4,906,013	380	3,191,864	–1,714,150
Preeclampsia after ambulatory care	577	5,698,412	442	4,560,054	–1,138,357
Total medical costs	6084	66,469,362	6084	63,506,433	–2,962,929
sFlt-1/PlGF evaluation	0	—	6084	856,627	+856,627
Overall costs
Total	6084	66,469,362	6084	64,363,060	–2,106,301
Per patient	6084	10,925	6084	10,579	–346

PlGF: placental growth factor; sFlt-1: soluble fms-like tyrosine kinase-1.